Please ensure Javascript is enabled for purposes of website accessibility

With COVID-19 Variant Threats Rising, Why Are Vaccine Stocks Falling?

By Dan Caplinger - Jul 7, 2021 at 6:27PM

Key Points

  • Vaccine stocks took a bigger hit than the overall market on Wednesday.
  • Nervousness about the delta variant appears to be one of the causes.
  • However, such worries could actually boost sales for these stocks, making their declines seem unwarranted.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Stock markets moved slightly higher despite general worries.

The stock market has been choppy this week, and Wednesday brought some new fears to the table. Market participants are looking closely at rising incidence of new COVID-19 variants, which could threaten to bring yet another wave of cases to areas where vaccination rates have been less than ideal. By the end of the day, major market benchmarks like the Dow Jones Industrial Average (^DJI 0.71%), S&P 500 (^GSPC 0.19%), and Nasdaq Composite (^IXIC 0.00%) had managed to recover their lost ground, but many investors remain nervous.

Index

Percentage Change

Point Change

Dow

+0.30%

+104

S&P 500

+0.34%

+15

Nasdaq Composite

+0.01%

+1

Data source: Yahoo! Finance.

One thing that was somewhat surprising was the behavior of vaccine stocks amid worries about new COVID-19 variants. Moderna (MRNA -4.99%), BioNTech (BNTX -1.30%), and Novavax (NVAX 1.37%) were all sharply lower on the day. Below, we'll look more closely at the moves to try to figure out what's going on.

Big losses in the vaccine area

The declines in vaccine stocks  were quite substantial. BioNTech made out relatively well with a 4% decline. However, Moderna dropped almost 5% on the day, and Novavax was the hardest hit, falling 14%. Other vaccine hopefuls were also weaker, as Inovio Pharmaceuticals (INO -2.87%) dropped almost 7% and Ocugen (OCGN -3.82%) lost nearly 5%.

Medical professional administering shot to patient.

Image source: Getty Images.

Most analysts attributed the declines in vaccine stocks to the delta variant of COVID-19. The delta variant is much more contagious than earlier variants, and it has become the most prevalent cause of COVID-19 in the U.S. recently. The Centers for Disease Control and Prevention recently estimated that slightly over half of U.S. COVID-19 cases are now coming from the delta variant.

The reason for concern seems to stem from the possibility that as COVID-19 variants evolve, they'll eventually get to the point at which current versions of vaccines are no longer effective. At least based on preliminary data, that doesn't seem to be the case with the delta variant. Existing vaccines from Moderna and BioNTech offer protection against the delta variant, albeit with some indications that efficacy might be somewhat reduced compared to earlier variants.

Opportunity abounds

However, declines in vaccine stocks make little sense in light of ongoing worries about COVID-19. The reasons are simple. First, greater awareness of the importance of vaccination to fight future variant mutations should boost sales of currently available vaccines from these companies.

But even more importantly, investors seem to assume that vaccine producers are standing still. Just as the virus can adapt to changing conditions, companies fighting the virus can adapt to the mutations, looking at ways to improve on existing vaccines. That might involve offering booster shots to those who've already received vaccinations, or it could eventually lead to entirely different vaccination regimens that could prove effective in fighting more aggressive strains of the virus. Sales of those new and existing products could actually help boost vaccine producers' longer-term prospects.

With much of the world only now getting their chance to obtain and distribute vaccines to their populations, nervousness about vaccine stocks seems premature at best. If weakness continues, it'll be hard not to see lower prices for shares of vaccine makers as an opportunity for investors to take advantage of what in hindsight might well look like a bargain.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. and Nasdaq. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$167.96 (-4.99%) $-8.82
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$34,152.01 (0.71%) $239.57
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$4,305.20 (0.19%) $8.06
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
^IXIC
$13,128.05 (0.00%) $0.00
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$42.88 (1.37%) $0.58
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$2.71 (-2.87%) $0.08
BioNTech SE Stock Quote
BioNTech SE
BNTX
$160.37 (-1.30%) $-2.11
Ocugen, Inc. Stock Quote
Ocugen, Inc.
OCGN
$2.77 (-3.82%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.